FDA’s economist in chief Foes and friends of Mark McClellan agree on at least one point: The Food and Drug […]

FDA’s economist in chief Foes and friends of Mark McClellan agree on at least one point: The Food and Drug

Biotech IPOs; don’t let the numbers deceive Take the biotechnology industry, which in 2003 raised $16.7 billion in capital —

Biotech IPOs; don’t let the numbers deceive Take the biotechnology industry, which in 2003 raised $16.7 billion in capital —

Purple Haze The prospects of a medicinal version of cannabis being produced have never been better but manufacturers are still

Financial Snapshot For December 2003 Bulls Charge Ahead

What’s Next for Pharma? Experts from the Tufts Center for the Study of Drug Development discuss the outlook for R&D,

What’s Next for Pharma? Experts from the Tufts Center for the Study of Drug Development discuss the outlook for R&D,

India: Big Pharma’s New Promised Land? For years, software companies have known that they can slash costs by hiring eager,

India: Big Pharma’s New Promised Land? For years, software companies have known that they can slash costs by hiring eager,